



Design of *Gaussia* luciferase-based bioluminescent stem-loop probe for sensitive detection of HIV-1 Nucleic acids

| | |
|-------------------------------|--|
| Journal: | <i>Analyst</i> |
| Manuscript ID | AN-ART-01-2018-000047.R1 |
| Article Type: | Paper |
| Date Submitted by the Author: | 10-Mar-2018 |
| Complete List of Authors: | Joda, Hamdi; University of Miami Miller School of Medicine, Biochemistry & Molecular Biology Moutsopoulos, Angeliki ; University of Miami Miller School of Medicine, Biochemistry & Molecular Biology; University of Miami, Chemistry Stone, Geoffrey ; University of Miami School of Medicine, Microbiology & Immunology Daunert, Sylvia; University of Miami Miller School of Medicine, Biochemistry and Molecular Biology Deo, Sapna; University of Miami Miller School of Medicine, Biochemistry & Molecular Biology |
| | |

Design of *Gaussia* luciferase-based bioluminescent stem-loop probe for sensitive detection of HIV-1 nucleic acids

Hamdi Joda¹, Angeliki Moutsiopoulou^{1,2}, Geoffrey Stone³, Sylvia Daunert¹ and Sapna Deo^{1*}

¹Department of Biochemistry and Molecular Biology

Miller School of Medicine, University of Miami

²Department of Chemistry, University of Miami

³Department of Microbiology and Immunology

Miller School of Medicine, University of Miami

*Corresponding author, sdeo@med.miami.edu

Abstract

Here we describe the design of a bioluminescent stem-loop probe for the sensitive detection of HIV-1 spliced RNA. In this study, we employed *Gaussia* luciferase (GLuc), a bioluminescent protein that has several advantages over other bioluminescent proteins, including smaller size, higher bioluminescent intensity, and chemical and thermal stability. GLuc was chemically conjugated to the DABCYL-modified stem-loop probe (SLP) and was purified with a 2-step process to remove unconjugated GLuc and SLP. The binding of the target RNA to the loop region of the SLP results in the open conformation separating the stem part of SLP. GLuc conjugated to the stem acts as a reporter that produces light by a chemical reaction upon adding its substrate, coelenterazine in the presence of the target, while DABCYL serves as a quencher of bioluminescence in the closed conformation of SLP in the absence of the target. The optimized GLuc based-SLP assay resulted in a signal-to-background ratio of 47, which is the highest reported with bioluminescent SLPs and is significantly higher compared to traditional fluorescent-based SLPs that yield low signal to background ratio. Moreover, the assay showed an excellent selectivity against a single and double mismatched nucleic acid target, low detection limit, and ability to detect spiked HIV-1 RNA in human serum matrix.

Introduction

Stem-loop probe (SLP), or molecular beacon (MB), is a self-complementary, single-stranded oligonucleotide with a hairpin-like structure that can undergo a structural change from closed to open conformation upon hybridization of complementary oligonucleotide target.¹ The structural change can be monitored by conjugating a fluorophore-quencher pair to the SLP probe such that the binding of target nucleic acid to the loop region results in the separation of fluorophore-

1
2
3 quencher pair resulting in the emission of fluorescence, which can be correlated with the
4 concentration of nucleic acid target. This classical SLP and its various modifications have been
5 employed in nucleic acid detection for a variety of applications including nucleic acid
6 hybridization,¹⁻³ real time polymerase chain reactions (RT-PCR),^{4, 5} RNA hybridization in living
7 cells,^{6, 7} and DNA-protein interaction.⁸ Beside the classical design of SLP with fluorophore-
8 quencher pair, different labels have been reported to improve sensitivity of SLP-based assays.
9 As an alternative to the fluorophore, other signaling reporters such as quantum dots (QD)⁹ and
10 metal complexes^{10, 11} have been used. Likewise, enhancement of quenching capability has been
11 demonstrated using gold nanoparticle (AuNP),¹² silver nanoparticle (AgNP),¹³ graphene oxide,¹⁴
12 and carbon nanotubes.¹⁵
13

14
15
16
17
18
19 Our laboratory was the first to demonstrate the use of a protein reporter, specifically a
20 bioluminescent protein, Renilla luciferase (Rluc), in the development of SLP.¹⁶ This
21 bioluminescent SLP showed a higher signal-to-background (S/B) ratio and lower detection limit
22 when directly compared to a fluorescent reporter-based SLP.¹⁶ The high sensitivity achieved
23 was due to the fact that the bioluminescence emission was generated from a chemical reaction
24 and did not require any excitation source, significantly reducing the background noise typically
25 observed with fluorescence-based reporters. Low background observed with bioluminescent
26 reporters also allows for direct target detection in complex matrices. In a recent study, a
27 modular design of molecular beacon based on bioluminescence resonance energy transfer was
28 developed using a bioluminescent protein Nanoluc as the donor and Cy3 as the acceptor
29 yielding a pM detection limit.¹⁷
30
31

32
33
34
35
36
37 A prior report from our laboratory that employs bioluminescent protein showed promising results
38 when bioluminescent reporter was used in the SLP design.¹⁶ However, there is still a room for
39 further improvement in the bioluminescent SLP design in terms of size and activity of the
40 bioluminescent protein. This prompted us to evaluate the use of other bioluminescent proteins
41 that can further enhance the design of SLP to achieve better performance in terms of sensitivity
42 and other analytical parameters. Specifically, in this report we evaluated Gaussia luciferase
43 (GLuc) as a bioluminescent reporter in the development of a SLP for the detection of a spliced
44 HIV-1 RNA. GLuc is the smallest coelenterazine-dependent luciferase and consists of 185
45 amino acids (19.9 kDa).¹⁸ It catalyzes the oxidation of coelenterazine to emit light at 480 nm and
46 does not need ATP or other co-factors for bioluminescence activity.¹⁸ Apart from being small
47 enough to potentially reduce steric hindrance for stem closure in the SLP design, GLuc has
48 significantly higher bioluminescent activity than most other luciferases. For example,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 bioluminescence intensity is much stronger (over 200 fold) than that of RLuc¹⁸ and is
4 comparable to the furimazine-dependent Nanoluc. GLuc is highly stable under a wide range of
5 temperatures (up to 95 °C)¹⁹ and in an acidic environment (down to pH 1.5),²⁰ whereas RLuc is
6 stable up to 37 °C and pH (~7.4) and Nanoluc is stable up to 55°C and pH (~7-9).²¹ These
7 properties of GLuc make it an attractive reporter in terms of bioconjugation and bioanalytical
8 applications. Therefore, it has been widely used for *in-vitro* and *in-vivo* imaging of tumor cells,²²
9 gene expression analysis,¹⁸ protein–protein interaction study,²³ immunoassay development,²⁴
10 and DNA hybridization.²⁵ We hypothesized that the small size of GLuc, high bioluminescence
11 emission, and temperature and pH stability compared to other bioluminescent proteins would
12 result in GLuc-based SLP with superior performance. We employed DABCYL as the quencher
13 in this study since its absorption maximum overlaps well with the emission spectrum of GLuc.
14

15
16 In this manuscript, we demonstrate the design of Gluc-based SLP for the detection of HIV-1
17 RNA corresponding to the 3/5 splice junction in HIV-1 infected cells.²⁶ Viral persistency has
18 been a challenge with HIV,²⁷⁻²⁹ Herpes,³⁰ Measles,³¹ Varicella,³² etc. With effective antiretroviral
19 therapy, the level of plasma HIV-1 RNA falls below the detection limit of clinical assays (50
20 copies/ml).³³ However, the virus cannot be completely eradicated, and a latent form of HIV-1
21 infection may persist in CD4⁺ cells that leads to HIV viral reactivation after interruption of the
22 therapy.³⁴ Typically, a number of pretreatment steps and cell isolation steps are performed prior
23 to RNA detection,³⁵ which prolongs the detection time and reduces the reliability of the method.
24 The gold standard method for measuring HIV persistence is the quantitative viral outgrowth
25 assay.³⁶⁻³⁸ This assay is performed on purified resting CD4⁺ T cells isolated from a patient,
26 which are then activated to induce viral replication. After about two weeks the viral outgrowth is
27 analyzed using ELISA assay or qPCR. In that respect, the use of bioluminescence detection
28 provides a convenient alternative to ELISA or qPCR for sensitive detection of HIV following a
29 viral outgrowth assay, as only minimal pretreatment is required and bioluminescence can be
30 performed rapidly following cell lysis. Further, our strategy combines the enhanced sensitivity of
31 bioluminescence with the specificity of stem-loop probes, which is key when developing
32 methods for sample detection in physiological matrices.
33

34 **Materials and methods**

35 **Materials**

36 All purchased chemicals were used without further purification. Monobasic sodium phosphate
37 anhydrous, dibasic sodium phosphate heptahydrate, imidazole, Tris-HCl, sodium chloride,
38 Tween 20, 2-mercaptoethanol (β -ME), and nonyl phenoxy polyethoxy ethanol (NP-40) were
39
40
41
42
43
44
45
46
47

1
2
3 purchased from Sigma-Aldrich (St Louis, MO). Slide-A-Lyzer Dialysis G2 Cassettes, Pierce
4 Centrifuge Column, Zeba desalt spin columns (7 kDa MWCO) and Bicinchoninic Acid (BCA)
5 Protein Assay Kit were obtained from Thermo Fisher Scientific (Waltham, MA). Succinimidyl 4-
6 hydrazinonicotinate acetone hydrazone (HyNic) was purchased from Solulink Biotechnologies
7 (San Diego, CA). Isopropyl-1-thio- β -D-galactopyranoside (IPTG) and 1X ProBlock™ Gold
8 Bacterial Protease Inhibitor Cocktail were purchased from Gold Biotechnology Inc. (St. Louis,
9 MO). Ni-NTA agarose was obtained from Qiagen (Valencia, CA). 4–20% Mini-PROTEAN®
10 TGX™ precast polyacrylamide gels were supplied by Bio-Rad Laboratories Inc. (Hercules,
11 California). Streptavidin resin was purchased from G-Biosciences, (St. Louis, MO). 96-well,
12 black, non-binding microplate was purchased from Greiner Bio-One Inc. (Monroe, NC). Native
13 coelenterazine was provided by NanoLight™ Technology (Prolume Ltd., Pinetop, AZ) and
14 prepared in 1 mL of acidified methanol to make 1 mg/mL. Stem-loop probe (SLP) with 5'-amino
15 and 3'-DABCYL modification (Table 1) was purchased from TriLink Biotechnologies (San Diego,
16 CA), all other synthetic oligonucleotides targets: fully matched (FM) HIV-1 DNA target, HIV-1
17 RNA target, DNA with single mismatch (SM), double mismatches (DM), and biotin modified
18 target were purchased as lyophilized powder from Sigma-Aldrich (St Louis, MO).
19
20
21
22
23
24
25
26
27
28
29

| | |
|-------------------------------|--|
| SLP | NH ₂ -C6-CGTC <u>ACTCCGCTTCTTCCTTGTTATGTAGTGACG</u> -DABCYL |
| Biotinylated oligo | ACATAACAAGGAAGAAGCGGAGTGACG –TEG Biotin |
| HIV-1 DNA target | AATATCAAGCAGGACATAACAAGGAAGAAGCGGAGACAGCGACGAA |
| HIV-1 RNA target | AAUAUCAAGCAGGACAUAACAAGGAAGAAGCGGAGACAGCGACGA |
| Single mismatch (SM) | AATATCAAGCAGGACATAACA <u><i>A</i></u> TGAAGAAGCGGAGACAGCGACGAA |
| Double mismatches (DM) | AATATCAAGCAGGACATAACA <u><i>A</i></u> TGAAGAA <u><i>A</i></u> CGGAGACAGCGACGAA |

30
31
32
33
34
35
36
37
38
39
40
41
42
43 Table 1. sequences of SLP (underlined bases are complementary to the targets), biotin-labeled
44 DNA, HIV-1 DNA target, HIV-1 RNA target, single mismatched DNA, double mismatched DNA.
45 Mismatched bases are shown in italic and underlined.
46
47
48
49

50 **Methods**

51 ***Expression and purification of *Gaussia luciferase****

52
53 The gene for the *Gaussia luciferase* (GLuc) was cloned into the pCold-I cold-shock expression
54 vector and transformed into Origami 2 *E. coli*. For expression, a culture of 5 mL was grown
55
56
57
58
59
60

1
2
3 overnight at 37 °C in terrific broth containing 0.1 mg/mL ampicillin. This culture was then used to
4 inoculate 300 mL of the same broth and was grown at 37 °C to an OD₆₀₀ nm of ~1.6. After that,
5 the cells were centrifuged and resuspended in fresh media with antibiotic and put in an ice bath
6 for 1 h to initiate cold-shock. Subsequently, expression was induced by adding 0.1 mM
7 isopropyl-1-thio-β-D-galactopyranoside (IPTG) and incubated overnight at 15 °C. The cells were
8 pelleted by centrifugation and resuspended in Lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM
9 sodium chloride, 10 mM imidazole, 1% (v/v) nonyl phenoxy polyethoxy ethanol (NP-40), 0.2%
10 (v/v) Tween 20, and 10 mM 2-mercaptoethanol (β-ME). Before sonication, 1X ProBlock™ Gold
11 Bacterial Protease Inhibitor Cocktail was added to the cell suspension then sonicated with
12 microtip probe (Model 500 Sonic Dismembrator, Fisher Scientific, Pittsburgh, PA) on ice bath for
13 20 min with a 0.5 s on/off pulse sequence.
14
15
16
17
18
19
20

21 The lysate was centrifuged at 17000 x g at 4 °C for 30 min to remove the insoluble material and
22 the supernatant was filtered through 0.45 μm filter followed by 0.22 μm filter. The filtered crude
23 protein was then incubated with Ni-NTA agarose at room temperature for 60 min, poured onto
24 Pierce Centrifuge Column and unbound proteins were removed by a flow through using gravity
25 flow. The beads were washed with 10 column volumes of lysis buffer followed by 20 column
26 volumes of a wash buffer (50 mM Tris-HCl pH 8.0 containing 150 mM sodium chloride and 20
27 mM imidazole). The protein was eluted with an elution buffer of 50 mM Tris-HCl pH 8.0
28 containing 150 mM sodium chloride, and 150 mM imidazole in 6 tubes, each about 1 column
29 volume. The eluted GLuc from each elution fraction was analyzed by SDS-PAGE using a
30 4–20% Tris-Glycine gel according to the manufacturer's instructions.
31
32
33
34
35
36

37 Subsequently, eluted GLuc was dialyzed into a phosphate buffered saline (PBS, 100 mM
38 sodium phosphate pH 7.2 and 150 mM sodium chloride) using Slide-A-Lyzer Dialysis G2
39 Cassettes with 3.5 kDa molecular weight cut-off (MWCO) then stored at 4 °C until further use.
40 Protein concentration was measured using the Bicinchoninic Acid (BCA) Protein Assay Kit
41 according to the manufacturer's instructions.
42
43
44
45

46 ***Conjugation of the stem-loop probe (SLP) to GLuc***

47 Conjugation of the SLP with GLuc was carried out using aldehyde-amine bioconjugation
48 chemistry by adopting a protocol used from Solulink Biotechnologies (<http://www.solulink.com/>).
49 Briefly, SLP with 5'-amino modification was chemically converted to a benzaldehyde moiety by
50 adding 50X excess of succinimidyl 4-formylbenzoate (SFB) in a modification buffer (100 mM
51 sodium phosphate buffer pH 7.4, 150 mM sodium chloride). In parallel, amine residues of
52 lysines on GLuc were modified with 20X excess of succinimidyl 4-hydrazinonicotinate acetone
53
54
55
56
57
58
59
60

1
2
3 hydrazone (HyNic) in a modification buffer. Both reactions were incubated for 2 h at room
4 temperature. Next, both reactions were desalted into a conjugation buffer (100 mM sodium
5 phosphate, 150 mM sodium chloride, pH 6.0 buffer) using Zeba desalt spin columns, 0.5 mL,
6 according to the manufacturer's protocol. Subsequently, SFB-modified oligonucleotide was
7 added in 4X excess to hydrazine-modified GLuc and conjugation reaction was performed for 2 h
8 at room temperature followed by overnight at 4 °C. The conjugation of GLuc with SLP (G-SLP)
9 was evaluated by SDS-PAGE using a 4– 20% Tris-Glycine gel.
10
11
12
13

14 ***Purification of unconjugated GLuc and SLP***

15
16 After conjugation, purification was necessary to remove any un-conjugated SLP and GLuc.
17 Purification was performed in a two-step process: the first step involved removing unconjugated
18 SLP using Ni-NTA agarose; while in the second step, unconjugated GLuc was removed using
19 streptavidin resin. For the first step, conjugation mixture was incubated in 0.5 mL Ni-NTA
20 agarose resin in Pierce Centrifuge Column for 1 h allowing for binding of His-tagged GLuc
21 (unconjugated GLuc and G-SLP). The flow-through containing unconjugated SLP was removed
22 followed by elution of unconjugated GLuc and G-SLP in an elution buffer. For the second step,
23 first 20 µM of a short biotinylated oligonucleotide complementary to the SLP (Table 1) was
24 added to 400 µL streptavidin resin in Pierce Centrifuge Column. The eluted mixture of
25 unconjugated GLuc and G-SLP was then added and incubated for >2 h at 37 °C to allow G-SLP
26 to hybridize with complementary biotinylated oligonucleotide. The flow-through containing
27 unconjugated GLuc was removed, and G-SLP was eluted by dehybridization in hot water. After
28 purification, the conjugation of GLuc with SLP (G-SLP) was evaluated by SDS-PAGE and silver
29 staining using Thermo Scientific Pierce Silver Stain Kit according to the manufacturer's
30 instruction.
31
32
33
34
35
36
37
38
39
40

41 ***HIV-1 RNA assay Development and optimization***

42 **Hybridization buffer optimization**

43
44 A 20 nM of G-SLP and 50 nM HIV-1 synthetic DNA target in different hybridization buffers were
45 added into a 96-well microplate in a total volume of 100 µL. Hybridization buffers employed for
46 this study were: 100 mM sodium phosphate buffer pH 7.4, 1 mM EDTA; 100 mM sodium
47 phosphate buffer pH 7.4, 75 mM sodium chloride buffer; 100 mM sodium phosphate buffer pH
48 7.4, 150 mM sodium chloride; 100 mM sodium phosphate buffer pH 7.4, 300 mM sodium
49 chloride; 75 mM sodium chloride, 7.5 mM trisodium citrate buffer pH 7.4; 150 mM sodium
50 chloride, 15 mM trisodium citrate buffer pH 7.4; 300 mM sodium chloride, 30 mM trisodium
51
52
53
54
55
56
57
58
59
60

1
2
3 citrate buffer pH 7.4; 10 mM Tris buffer pH 7.4, 150 mM sodium chloride; and 10 mM Tris buffer
4 pH 7.4, 500 mM sodium chloride. Hybridization reaction was performed for 60 min at 37 °C.
5
6 Bioluminescence signal was measured using Clariostar Optima (BMG Labtech, Ortenberg,
7 Germany) after injection of 50 µL of coelentraine substrate (6 µM) prepared in 100 mM sodium
8 phosphate buffer pH 7.4, 150 mM sodium chloride. Signal-to-background ratio was calculated
9 by measuring the ratio of the emission intensity in the absence and presence of target (50nM).
10
11

12 13 **Hybridization time and temperature optimization**

14
15 Hybridization assay was performed in a 96-well, black, non-binding microplate. Both G-SLP (20
16 nM) and HIV-1 synthetic target (50 nM) in a hybridization buffer (10 mM Tris buffer pH 7.4 with
17 500mM NaCl) were added into microplate wells in a total volume of 100 µL. Then the microplate
18 was sealed with adhesive tape to prevent evaporation and incubated for 15 and 60 mins at 22,
19 37, and 45 °C in a temperature-controlled incubator. Bioluminescence signal was measured as
20 described previously.
21
22

23 24 **Assay sensitivity and specificity**

25
26 To generate a dose-response curve, hybridization assay was performed in a 96-well, black,
27 non-binding microplate. 20 nM of G-SLP and different amounts from 0.1 to 50 nM of HIV-1 DNA
28 synthetic target in a hybridization buffer were added into microplate wells in a total volume of
29 100 µL and incubated for 60 mins at 22, 37, and 45 °C. Bioluminescence signal was measured
30 as described previously.
31
32

33
34 Assay specificity was evaluated by hybridizing 20 nM G-SLP with fully matched (FM), single
35 mismatched (SM) and double mismatched (DM) synthetic HIV-1 target (Table 1) in various
36 concentrations, and comparing the bioluminescence signal after hybridization for 1 h at 37 °C.
37
38

39 40 **Detection of HIV-1 target RNA in a clinical sample matrix**

41
42 To simulate clinical sample analysis, different known concentrations of the synthetic HIV-1
43 target RNA were spiked in 1:10 diluted pooled human serum (Sigma-Aldrich). G-SLP (20 nM)
44 was added to serum samples, and hybridization was performed by incubation for 1 h at 37 °C.
45 Bioluminescence signal was measured as described above.
46
47
48

49 50 **Results and Discussion**

51
52 Stem-loop probe is a versatile design of hybridization probe in biosensing applications offering
53 high specificity and sensitivity. In comparison to solid phase assays, which require multiple
54 wash steps to decrease the non-specific adsorption and high background signal, SLP-based
55
56
57
58
59
60

1
2
3 assay is a single-step, mix-and-measure assay. In this manuscript, we describe the design of a
4 bioluminescent SLP that employs GLuc as the reporter protein and DABCYL as the quencher
5 moiety. GLuc is the smallest known coelenterazine-dependent luciferase and is bright and
6 stable at varied temperature and pH, which makes it an attractive reporter for use in the
7 development of SLP assay.
8
9
10

11 **Conjugation of GLuc with SLP**

12
13 GLuc was expressed and purified following the protocol developed in our laboratory. SDS-
14 PAGE was performed to verify the size and purity of GLuc protein. Purified GLuc was then
15 conjugated to the DABCYL-modified SLP using SFB/HyNic chemistry as detailed in the
16 methods section (Figure 1A). SDS-PAGE analysis (ESI 1) confirmed the successful conjugation
17 between GLuc and SLP. Following conjugation, removal of un-conjugated GLuc and SLP was
18 performed to reduce background stemming from the presence of unconjugated GLuc and signal
19 depression resulting from unconjugated SLP. Assay sensitivity and signal-to-background (S/B)
20 ratio depend significantly on the purification step. Purification of G-SLP was performed in a 2-
21 step process as detailed in the methods section. Following purification, SDS-PAGE with silver
22 stain was performed (Fig. 1B) and showed 2 distinct bands around 37 kDa and 50 kDa that
23 corresponded to GLuc-SLP mono- and di-conjugates, respectively, as determined from the
24 molecular weight of the stem-loop relative to the purified Gluc shown in the adjacent well. Based
25 on the reproducibility of this analysis, the overwhelming majority of Gluc-SLP were represented
26 as a $\leq 1:2$ conjugation ratio and provided a foundation for the excellent S/B ratio observed
27 experimentally. This also provided evidence to suggest that higher-order conjugation was
28 unfavorable, whether as a factor of appropriate molar ratios during conjugation or as steric
29 effects that biased against proximal functionalization.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. A: Schematic of chemical conjugation reaction between SLP and GLuc protein. B: SDS-PAGE showing analysis of GLuc before and after conjugation with SLP, visualized by silver staining. Lane 1; protein ladder, Lane 2; unconjugated GLuc, Lane 3; purified GLuc-SLP.

For attaching SLP to GLuc, we have chosen amine-reactive bioconjugation chemistry through lysine residues on GLuc because it offers an easy, simple method that doesn't require protein mutation and capitalizes on the availability of commercial kits. The possibility of attaching multiple SLPs per bioluminescent protein offers a platform for increasing S/B ratio by decreasing the background. Over-conjugation of lysine residues may, indeed, affect the activity of a protein, although this was difficult to observe in our case due to the ever-present quenching effect of the DABCYL. If polyconjugates provided any artifacts within the assay system, the effect would be reproducible due to homogeneity and only apparent at extremely low target concentrations. Mitigation is as simple as shifting the dynamic range lower by reducing the total probe concentration. Conversely, conjugation through sulfhydryl or other groups often results in the loss of protein activity as these residues are typically essential for protein function. For example, GLuc has several Cys residues that are essential for its activity. This can also be mitigated by the introduction of a non-native conjugation site, as we demonstrated previously through a Tyr introduced at the N-terminus of Gluc to achieve site-specific conjugation since Gluc lacks Tyr residues.²⁴

Assay Condition Optimization

After the purification of GLuc-conjugated SLP, assay conditions such as hybridization buffer, temperature, and time were optimized in order to achieve the best S/B ratio. Buffer composition and salt concentration are known to play an important role in hybridization assay specificity and sensitivity. Therefore, we investigated the effect of several buffers with varying ionic strength on hybridization efficiency by monitoring the S/B ratio. Figure 2 illustrates that the S/B ratio varied depending on the buffer composition. We found that the use of 10 mM Tris buffer pH 7.4 with 500 mM NaCl is the optimal hybridization buffer, resulting in an S/B ratio of about 47. This ratio is 5.2-fold higher compared to our previous study where Renilla luciferase (RLuc) was used as a reporter in the design of bioluminescent stem-loop probe (BSLP), where the S/B ratio was 9.¹⁶ As predicted, the GLuc S/B ratio increased relative to RLuc, and this was likely due primarily to the smaller size of GLuc. Besides presenting a less massive strain on the stem terminus that would reduce thermodynamic instability, the probability of the quencher being oriented at the outer limits of the Förster radius would be minimized. Stability to changes in pH and temperature also likely contributed to better performance of GLuc-based SLP.




Figure 2. Signal-to-background ratio (S/B) evaluation using different hybridization buffers in the presence of 50 nM of target. G-SLP probe and target were hybridized for 60 min at 37 °C.

1
2
3 Buffers used for S/B ratio evaluation are: (1) 100 mM sodium phosphate buffer pH 7.4, 1 mM
4 EDTA; (2) 100 mM sodium phosphate buffer pH 7.4, 75 mM sodium chloride; (3) 100 mM
5 sodium phosphate buffer pH 7.4, 150 mM sodium chloride; (4) 100 mM sodium phosphate
6 buffer pH 7.4, 300 mM sodium chloride; (5) 75 mM sodium chloride, 7.5 mM trisodium citrate
7 buffer pH 7.4; (6) 150 mM sodium chloride, 15 mM trisodium citrate buffer pH 7.4; (7) 300 mM
8 sodium chloride, 30 mM trisodium citrate buffer pH 7.4; (8) 10 mM Tris buffer pH 7.4, 150 mM
9 sodium chloride; (9) 10 mM Tris buffer pH 7.4, 500 mM sodium chloride.
10
11
12
13
14
15

16 Following optimization of the hybridization buffer composition, hybridization time and
17 temperature parameters were assessed. It has been reported that a SLP with a short stem has
18 a lower melting temperature (T_m), which can easily open even in the absence of the
19 complementary target. This results in a high background and low S/B ratio.³⁹ While SLP with a
20 long stem will give stable SLP (high T_m) with a low background and high S/B ratio, it is not
21 favorable due to its slow hybridization kinetics in the presence of the target. Therefore, SLP
22 should be carefully designed with optimum assay stringency to obtain the highest S/B ratio as
23 well as an ultrasensitive and specific assay. Melting temperature and secondary structure of the
24 SLP and SLP-target duplex were analyzed using the OligoAnalyzer 3.1 tool of IDT
25 (<https://www.idtdna.com/calc/analyser> Integrated DNA Technologies, Inc., USA). Our SLP
26 consists of 34 nucleotides and was designed with 20 nucleotides at the loop region and stem
27 with 7 bp length. Theoretical melting temperature (T_m) of the SLP was found to be 61.6 °C using
28 Na^+ concentration of 0.5 M. Theoretical T_m of the SLP-target duplex was found to be 74.8 °C
29 ($\text{Na}^+ = 0.5 \text{ M}$). To test our designed SLP, a 50 nM of the target was hybridized with G-SLP for
30 15 and 60 min at room temperature (22 °C), physiologic temperature (37 °C), and at 45 °C. The
31 bioluminescence result was then compared with control without the target added. As predicted,
32 the S/B ratio was higher in the case of 60 min hybridization in comparison to 15 min (Figure 3).
33 Furthermore, with 60 min hybridization time we observed that the S/B ratio increased gradually
34 with increase in assay temperature above 22 °C reaching more than two-fold at 45 °C.
35 Temperature is an important factor in all hybridization assays, as temperature closer to the
36 melting temperature of the stem facilitates opening of the self-complementary stem in the
37 presence of the target.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Signal/background ratio calculated for SLP assay performed with 50 nM target at different temperatures (22, 37 and 45 °C) for 15 (□) and 60 (■) min and compared to the control without the target.

Assay sensitivity and specificity

One of the important parameters in the assessment of bioassay performance is the assay sensitivity. To check for this, calibration curves were generated with different concentrations of synthetic HIV-1 DNA target from 0.1 to 50 nM at 22, 37 and 45 °C for 15 min and 60 min (Data not shown). The lowest limit of detection (LOD) was achieved using a 60 min hybridization time at 37 °C. LOD was estimated to be 0.045 nM with a linear dynamic range between 0 and 10 nM (Figure 4). Our study shows 9 times lower LOD using Gluc-SLP compared to using RLuc-SLP previously reported by our group,¹⁶ attesting to the advantage of using GLuc as a reporter over RLuc in the development of sensitive SLP assays. Moreover, our assay time (60 min) is shorter than in the previous report (180 min) where RLuc was employed in the bioluminescent SLP design.




Figure 4. Calibration curve obtained using G-SLP in the presence of various concentrations of HIV-1 DNA target. Assay was carried out for 60 min at 37 °C. Inset shows the linear range of the calibration curve, dotted lines represent linear fitting with 95% confidence interval. Each data point represents the average and standard deviation of three individual measurements. Some error bars that are not visible are obstructed by the symbols of the points.

Another important parameter for nucleic acid bioassays is the assay specificity, which is the ability to discriminate between base mismatches. In that regard, the specificity of our assay was evaluated with 20 nM of G-SLP hybridized with 0.5, 1, 5, 10 and 25 nM of fully matched (FM), single mismatched (SM), and double mismatched (DM) DNA (Table 1) for 60 min at 37 °C. An excellent selectivity was seen for the assay, as the recorded bioluminescence signals reveal that our G-SLP assay was able to distinguish the FM target with high selectivity in the presence of interfering targets with one or two nucleotide mismatches at different target concentrations (Figure 5).




Figure 5. Assay specificity, showing the bioluminescence signals for fully matched (-□-), single mismatched (•□•) and double mismatched (-▲) DNA targets. Assay was performed for 60 min at 37 °C, in the presence of 0.5, 1, 5, 10 and 25 nM targets concentration. Each data point represents the average and standard deviation of three individual measurements.

Spiked samples in serum

We performed a study to demonstrate the use of G-SLP assay for direct detection of HIV-1 RNA in a clinical sample matrix. For this, we spiked different amounts of the synthetic HIV-1 RNA target in human serum diluted to 10% in 10 mM Tris buffer pH 7.4, 500 mM NaCl, followed by incubation with G-SLP for 1 h at 37 °C. A calibration curve was generated as shown in Figure 6. This curve resulted in a linear range between 0 and 10 nM with LOD 0.1 nM, which is only about two-fold higher than the LOD obtained with synthetic HIV-1 DNA in a buffer matrix. Although the LOD was decreased in 10% serum, it is sufficient for direct detection of HIV-1 RNA in a patient sample following cell-line expansion. If more sensitive detection is required, HIV-1 can be concentrated from a larger blood volume using ultracentrifugation; then the RNA assay could be performed in buffer following HIV particle lysis or RNA extraction with commercially available

kits.




Figure 6. Calibration curve of G-SLP in the presence of various concentrations of RNA target in 10% serum. Assay was carried out for 1 h at 37 °C. Inset shows the linear range of the calibration curve, dots represent linear fitting with 95% confidence interval. Each data point represents the average and standard deviation of three individual measurements.

In conclusion, we have demonstrated that GLuc-based bioluminescent SLP results in a high S/B ratio yielding excellent sensitivity for the detection for target nucleic acid. GLuc, being smallest in size and brightest among the colenterazine-dependent bioluminescent proteins, contributes to the design of a superior SLP. The signal to background ratio obtained was the highest amongst the BSLPs reported to date. Additionally, GLuc is stable at high temperature, which should enhance the application of this construct for generic nucleic acid detection assays.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgement.

1
2
3 The work was supported through NIGMS funding (R01GM114321), the National Science
4 Foundation (CHE-1506740), and the State of Florida Department of Health. Sylvia Daunert
5 thanks the Miller School of Medicine of the University of Miami for the Lucille P. Markey Chair in
6 Biochemistry and Molecular Biology.
7
8
9
10


11 **References:**

- 12 1. S. Tyagi and F. R. Kramer, *Nat. Biotechnol.*, 1996, **14**, 303-308.
- 13 2. G. Yao and W. Tan, *Anal. Biochem.*, 2004, **331**, 216-223.
- 14 3. V. Beni, T. Zewdu, H. Joda, I. Katakis and C. O'Sullivan, *Anal. Bioanal. Chem.*, 2012,
15 **402**, 1001-1009.
- 16 4. D. Summerer and A. Marx, *Angew. Chem. Int. Ed.*, 2002, **41**, 3620-3622.
- 17 5. S. Tyagi, D. P. Bratu and F. R. Kramer, *Nat Biotech*, 1998, **16**, 49-53.
- 18 6. A. Jayagopal, K. C. Halfpenny, J. W. Perez and D. W. Wright, *J. Am. Chem. Soc.*, 2010,
19 **132**, 9789-9796.
- 20 7. D. L. Sokol, X. Zhang, P. Lu and A. M. Gewirtz, *Proc Natl Acad Sci USA*, 1998, **95**,
21 11538-11543.
- 22 8. J. J. Li, X. Fang, S. M. Schuster and W. Tan, *Angew. Chem. Int. Ed.*, 2000, **39**, 1049-
23 1052.
- 24 9. A. K. Chen, M. A. Behlke and A. Tsourkas, *Nucleic Acids Res.*, 2007, **35**, e105-e105.
- 25 10. H. S .Joshi and Y. Tor, *Chem. Commun.*, 2001, 549-550.
- 26 11. J. Li, W. Zhou, X. Ouyang, H. Yu, R. Yang, W. Tan and J. Yuan, *Anal. Chem.*, 2011, **83**,
27 1356-1362.
- 28 12. B. Dubertret, M. Calame and A. J. Libchaber, *Nat. Biotechnol.*, 2001, **19**, 365-370.
- 29 13. H.-I. Peng, C .M. Strohsahl, K. E. Leach, T. D. Krauss and B. L. Miller, *ACS Nano*, 2009,
30 **3**, 2265-2273.
- 31 14. C.-H. Lu, J. Li, J.-J. Liu, H.-H. Yang, X. Chen and G.-N. Chen, *Chemistry – A European*
32 *Journal*, 2010, **16**, 4889-4894.
- 33 15. R. Yang, J. Jin, Y. Chen, N. Shao, H. Kang, Z. Xiao, Z. Tang, Y. Wu, Z. Zhu and W. Tan,
34 *J. Am. Chem. Soc.*, 2008, **130**, 8351-8358.
- 35 16. E. A. Hunt and S. K. Deo, *Chem. Commun.*, 2011, **47**, 9393-9395.
- 36 17. W. Engelen, K. M. van de Wiel, L. H. H. Meijer, B. Saha and M. Merckx, *Chem.*
37 *Commun.*, 2017, **53**, 28.2865-62

- 1
- 2
- 3 18. B. A. Tannous, D.-E. Kim, J. L. Fernandez, R. Weissleder and X. O. Breakefield, *Mol.*
- 4 *Ther.*, 2005, **11**, 435-443.
- 5
- 6 19. T. Rathnayaka, M. Tawa, S. Sohya, M. Yohda and Y. Kuroda, *Biochimica et Biophysica*
- 7 *Acta (BBA) - Proteins and Proteomics*, 2010.1907-1902 ,1804 ,
- 8
- 9 20. S. Wiles, K. Ferguson, M. Stefanidou, D. B. Young and B. D. Robertson, *Appl. Environ.*
- 10 *Microbiol.*, 2005, **71**, 3427-3432.
- 11
- 12 21. M. P. Hall, J. Unch, B. F. Binkowski, M. P. Valley, B. L. Butler, M. G. Wood, P. Otto, K.
- 13 Zimmerman, G. Vidugiris, T. Machleidt, M. B. Robers, H. A. Benink, C. T. Eggers, M. R.
- 14 Slater, P. L. Meisenheimer, D. H. Klaubert, F. Fan, L. P. Encell and K. V. Wood, *ACS*
- 15 *Chemical Biology*, 2012, **7**, 1848-1857.
- 16
- 17 22. K. M. Venisnik, T. Olafsen, S. S. Gambhir and A. M. Wu, *Mol. Imag. Biol.*, 2007, **9**, 267-
- 18 277.
- 19
- 20 23. I. Remy and S. W. Michnick, *Nat. Methods*, 2006, **3**, 977-979.
- 21
- 22 24. A. Moutsiopoulou, E. Hunt, D. Broyles, C. A. Pereira, K. Woodward, E. Dikici, A. Kaifer,
- 23 S. Daunert and S. K. Deo, *Bioconjugate Chem.*, 2017, **28**, 1749-1757.
- 24
- 25 25. M. Verhaegen and T. K. Christopoulos, *Anal. Chem.*, 2002, **74**, 4378-4385.
- 26
- 27 26. D. F. Purcell and M. A. Martin, *J. Virol.*, 1993, **67**, 6365-6378.
- 28
- 29 27. D. Finzi, J. Blankson, J. D. Siliciano, J. B. Margolick, K. Chadwick, T. Pierson, K. Smith,
- 30 J. Lisziewicz, F. Lori, C. Flexner, T. C. Quinn, R. E. Chaisson, E. Rosenberg, B. Walker,
- 31 S. Gange, J. Gallant and R. F. Siliciano, *Nat. Med.*, 1999, **5**, 512-517.
- 32
- 33 28. J. K. Wong, M. Hezareh, H. F. Günthard, D. V. Havlir, C. C. Ignacio, C. A. Spina and D.
- 34 D. Richman, *Science*, 1997, **278**, 1291-1295.
- 35
- 36 29. J. D. Siliciano, J. Kajdas, D. Finzi, T. C. Quinn, K. Chadwick, J. B. Margolick, C. Kovacs,
- 37 S. J. Gange and R. F. Siliciano, *Nat. Med.*, 2003, **9**, 727-728.
- 38
- 39 30. B. Grinde, *Journal of Oral Microbiology*, 2013, **5**, 10.3402/jom.v3405i.3400.22766
- 40
- 41 31. J. L. Sever, *Reviews of Infectious Diseases*, 1983, **5**, 467-473.
- 42
- 43 32. E. Eshleman, A. Shahzad and R. J. Cohrs, *Future virology*, 2011, **6**, 341-355.
- 44
- 45 33. A. S. Perelson, P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz
- 46 and D. D. Ho, *Nature*, 1997, **387**, 188.
- 47
- 48 34. R. T. Davey, N. Bhat, C. Yoder, T.-W. Chun, J. A. Metcalf, R. Dewar, V. Natarajan, R. A.
- 49 Lempicki, J. W. Adelsberger, K. D. Miller, J. A. Kovacs, M. A. Polis, R. E. Walker, J.
- 50 Falloon, H. Masur, D. Gee, M. Baseler, D. S. Dimitrov, A. S. Fauci and H. C. Lane,
- 51 *Proceedings of the National Academy of Sciences*, 1999, **96**, 15109-15114.
- 52
- 53 35. D. D. Richman, J. A. McCutchan and S. A. Spector, *The Journal of Infectious Diseases*,
- 54 1987, **156**, 823-827.
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 36. T.-W. Chun, L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova,
4 K. Chadwick, J. Margolick, T. C. Quinn, Y.-H. Kuo, R. Brookmeyer, M. A. Zeiger, P.
5 Barditch-Crovo and R. F. Siliciano, *Nature*, 1997, **387**, 183.
6
7 37. J. D. Siliciano and R. F. Siliciano, in *Human Retrovirus Protocols: Virology and*
8 *Molecular Biology*, ed. T. Zhu, Humana Press, Totowa, NJ, 2005, DOI: 10.1385/1-
9 59259-907-9:003, pp. 3-15.
10
11 38. A. Fun, H. P. Mok, M. R. Wills and A. M. Lever, *Scientific Reports*, 2017, **7**, 43231.
12
13 39. A. Tsourkas, M. A. Behlke, S .D. Rose and G. Bao, *Nucleic Acids Res.*, 2003, **31**, 1319-
14 1330.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Sensitive detection of HIV-1 nucleic acids using Gaussia Luciferase based bioluminescent stem-loop assay



Conjugation of the stem-loop probe (SLP) to GLuc

G-SLP assay for HIV-1 nucleic acids detection

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60